Clinical Trial Detail

NCT ID NCT03291353
Title Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
Recruitment Withdrawn
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Michael Boyiadzis
Indications

acute myeloid leukemia

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.